Trials / Completed
CompletedNCT06863662
Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm
Efficacy and Safety of the Fixed-Dose Combination of Etoricoxib / Tizanidine Versus Etoricoxib in the Treatment of Patients With Acute Low Back Pain Associated to Muscle Spasm
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Laboratorios Silanes S.A. de C.V. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial. The aim of the study is to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib and tizanidine compared to etoricoxib alone in patients with acute low back pain associated with muscle spasms.
Detailed description
Researchers will compare the efficacy of a fixed-dose combination of etoricoxib and tizanidine versus etoricoxib alone in the treatment of acute low back pain associated with muscle spasms. Efficacy will be assessed by evaluating the average change in pain among patients who report improvement over the 7-day follow-up period. Adverse events related to the interventions will be recorded throughout the study. Participants will: * Be randomized into one of two intervention groups (Group A or Group B). * Attend three in-person clinic visits: Day 0 (baseline), Day 3, and Day 7 of follow-up. * Receive follow-up phone calls on Days 1 and 5. * Be allowed to take 500 mg of acetaminophen as rescue medication if needed, with prior authorization from the Principal Investigator.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etoricoxib + Tizanidine fixed dose | One sachet with 120 mg / 4 mg, dissolved in 100 mL of water |
| DRUG | Etoricoxib fixed dose | One sachet with 120 mg, dissolved in 100 mL of water |
Timeline
- Start date
- 2024-09-18
- Primary completion
- 2025-09-26
- Completion
- 2025-12-01
- First posted
- 2025-03-07
- Last updated
- 2026-01-09
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT06863662. Inclusion in this directory is not an endorsement.